Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu-64-TP3805 PET Imaging in Breast Cancer
NCT02810873Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2008
- Primary completion
- May 2012
- Modality
- Peptide-Drug Conjugates
01
Overview
Open-label trial of NV-VPAC1 in breast carcinoma (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of F-18-FDG Positive Lesions That Are Detected by the Copper Cu 64 TP3805 Analog at 4 hours. Started Sep 2008; status: terminated.
02
Drugs
NV-VPAC1
03
Conditions
breast carcinoma
Beyond the preview
Go deeper on NCT02810873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810873.